Background
Prasugrel is a 3 rd generation potent theinopyridine indicated for treatment of ST-elevation and non-ST elevation myocardial infarction (MI) according to current guidelines.
Some of the patients may require urgent or emergent coronary artery bypass grafting surgery (CABG) following pre-treatment with prasugrel and coronary angiography.
Surgical bleeding is significantly increased during and after thienopyridine therapy. 
According to the TRITON-TIMI-38 trial (CABG cohort), more bleeding occurred with prasugrel compared with clopidogrel up to 1 week after drug discontinuation.
The overall CABG related bleeding risk was 4 times higher with prasugrel. 
Guidelines recommend discontinuing prasugrel at least 7 days before surgery.
The pharmacodynamic basis for these recommendations is limited. 
The RECOVERY trial, assessed the offset of antiplatelet effect of prasugrel compared to clopidogrel in stable coronary disease patients.
A 7 day waiting period after prasugrel cessation provided platelet recovery closest to the 5-day waiting period for clopidogrel.
Platelet function testing could help guide surgical timing in thienopyridine-treated patients to minimize bleeding complications.
The evidence supporting such an approach is limited by the lack of firm cutoffs to predict bleeding events.
Aim
To monitor platelet reactivity in patients with acute MI pre-treated with prasugrel and referred for urgent CABG.
Methods
Included all patients with MI treated with prasugrel (60 mg loading and/or 10 mg maintenance dose) and referred for urgent CABG. Using the VerifyNow P2Y12 assay platelet function was measured at several intervals (1-2 days) from prasugrel last dose until surgery. Timing of surgery was determined according to platelet function test (<50% platelet inhibition) and clinical considerations Perioperative bleeding parameters included:
Chest tube blood drainage Hg drop Blood product transfusion Re-exploration due to bleeding 
Results
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Results
Platelet function
Results
Median time from prasugrel discontinuation to CABG was 6 days (minimum 3 -maximum 10)
Bleeding parameters 
Summary and Conclusions
This study is limited by it's small sample size and presents preliminary results.
Nevertheless, it seems that platelet monitoring after prasugrel discontinuation in patients with acute MI may aid in timing for urgent CABG and may reduce risk for bleeding.
It appears that after 5-6 days from discontinuation of prasugrel platelet function returns close to baseline values.
